Dishman Pharma gets EIRs for 3 sites from USFDA

Image
Press Trust of India New Delhi
Last Updated : Jul 14 2016 | 5:57 PM IST
Dishman Pharmaceuticals and Chemicals has received Establishment Inspection Report from the US health regulator for three of its facilities.
"Company's wholly owned subsidiary Carbogen Amcis AG, Switzerland has successfully completed United States Food and Drug Administration (USFDA) inspection for its two sites located at Aarau and Neuland without any adverse observations," Dishman Pharmaceuticals and Chemicals said in a BSE filing.
It has received the Establishment Inspection Report (EIR) for the same, it added.
"Now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA, Dishman said.
The company's site at Naroda has also completed successful USFDA inspection and received EIR for the same, the company added.
Shares of Dishman Pharmaceuticals and Chemicals today closed 2.66 per cent up at Rs 136.85 per scrip on BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 14 2016 | 5:57 PM IST

Next Story